截至2026年3月,Tiziana Life Sciences PLC鼻内Foralumab在长期治疗中耐受性良好

美股速递
May 19

截至2026年3月的数据显示,Tiziana Life Sciences PLC旗下药物——鼻内给药的Foralumab,在延长治疗期间展现出良好的耐受性。这一进展为相关治疗领域提供了积极信号。

长期用药的安全性是药物开发的关键考量。Foralumab在此方面的表现,为后续的临床研究与应用奠定了重要基础。其耐受性数据,将有助于进一步评估该疗法的潜力与风险。

研究结果的持续积累,对于理解药物特性至关重要。Tiziana Life Sciences PLC所公布的这一信息,反映了该候选药物在安全性方面的积极态势。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10